金吾财讯 | 丹麦公司 Gubra 与跨国药企艾伯维(ABBV)达成许可协议，将携手对 GUB014295 展开开发。GUB014295 是一种长效胰淀素（amylin）类似物，有望成为治疗肥胖症的同类最优药物。AbbVie 首席执行官Robert A. Michael表示：“在 AbbVie，我们专注于在仍存在大量未满足需求的领域改变患者护理的未来。与 Gubra 的合作标志着我们进入肥胖领域，为我们提供了一个极具吸引力的机会，既能满足患者需求，又能促进我们公司的长期增长。”GUB014295 目前处于 1 期临床试验阶段。GUB014295 是一种潜在的长效胰岛淀粉样肽类似物，是一种特异性激活胰岛淀粉样肽和降钙素受体的激动剂。胰岛淀粉样肽是一种饱腹激素，已被确定为治疗肥胖症的潜在治疗靶点，因为它可以激活大脑信号，抑制食欲，减少食物摄入，同时还可以作为延迟胃排空的抑制信号。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.